Corimmun, a Germany-based drug development company which spun off from the Universities of Würzburg and of Tübingen, has been sold to Janssen-Cilag, part of the Janssen Pharmaceutical Companies of US-based pharmaceutical group Johnson & Johnson. Corimmun received €680,000 ($855,000) of funding in 2008 from High-Tech Gründerfonds, Bayern Kapital and BioM in 2007. Corimmun’s main product…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
